# Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer

> **NCT04243616** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Medical College of Wisconsin** · enrollment: 36 (actual)

## Conditions studied

- Invasive Breast Cancer

## Interventions

- **DRUG:** Cemiplimab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin (not mandatory)
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT04243616
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-05
- **Primary completion:** 2025-08-11
- **Final completion:** 2030-08-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04243616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04243616, "Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT04243616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*